CURRENT EYE RESEARCH, vol.40, no.6, pp.585-591, 2015 (Peer-Reviewed Journal)
Article / Article
CURRENT EYE RESEARCH
Science Citation Index Expanded, Scopus
Antivascular endothelial growth factor, bevacizumab, retinopathy of prematurity, ENDOTHELIAL GROWTH-FACTOR, INJECTION, SAFETY, AVASTIN, BAYLEY, CHILD, ROP
Purpose: To evaluate the two-year follow-up of patients with type 1 retinopathy of prematurity (ROP) who received intravitreal bevacizumab (IVB) as adjunctive treatment.